Covalon seeks FDA approval for antimicrobial silver wound dressing

By Elaine Rigoli

Tampa, Fla., April 4 - Covalon Technologies Ltd. has made a 510(k) application for approval from the Food and Drug Administration for Collagran Ag, a collagen antimicrobial silver wound dressing.

Collagran Ag provides a combination of features and benefits found in advanced wound dressings and is indicated for use on decubitus ulcers, abrasions, lacerations, incisions, second degree burns and for reducing microbial contamination, according to a news release.

There is a shift toward antimicrobial silver ion releasing barrier dressings in treating advanced wounds, the release said.

The company said silver ion releasing dressings maintain a moist wound environment and provide optimal healing for decubitus and other wounds.

Covalon, located in Mississauga, Ont., develops patented therapeutic biomaterials for wound care and surgical applications and coatings.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.